The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis.
Duchenne muscular dystrophy
alendronate
bisphosphonate
children
vertebral fracture
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
31
08
2021
received:
16
03
2021
accepted:
03
09
2021
pubmed:
11
9
2021
medline:
19
3
2022
entrez:
10
9
2021
Statut:
ppublish
Résumé
Glucocorticoid-induced osteoporosis with vertebral fractures is frequent in patients with Duchenne muscular dystrophy (DMD). In this study, we evaluated the effects of oral bisphosphonate (BP) therapy on the prevalence and severity of vertebral fractures by vertebral morphometry assessment. We reviewed the records and radiographs of patients with DMD who had been treated with oral BP (weekly alendronate) and had undergone routine spine radiographic monitoring for glucocorticoid-induced osteoporosis at Cincinnati Children's Hospital Medical Center between 2010 and 2017. Study outcomes were thoracic and lumbar vertebral fracture prevalence and severity, assessed by Genant semiquantitative grading of vertebral morphometry, for up to 5 years of treatment. Fifty-two patients (median age, 11.8 years; 88% prepubertal; 31% nonambulatory) had been treated with long-term glucocorticoids (median duration, 4.7 years at BP start). Most patients (75%) had mild vertebral height loss or fractures (Genant grade = 0 or 1) at baseline. The prevalence of vertebral fractures at each year of treatment was not statistically different from that at baseline (P = .08-1.00). Serial radiographs showed no longitudinal change in severity by Genant grade in most vertebrae (64%-80%). Improvement in vertebral fracture grade was observed in some patients. We observed stable prevalence of vertebral fractures and no change in severity by Genant grade in most vertebrae for up to 5 years of treatment. Oral BP may mitigate development or progression of vertebral fractures and be beneficial for secondary prevention of glucocorticoid-induced osteoporosis in this population.
Substances chimiques
Diphosphonates
0
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
710-716Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177-189.
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347-361.
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251-267.
Tian C, Wong BL, Hornung L, et al. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26:760-767.
Joseph S, Wang C, Bushby K, et al. Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UKNorthStar database. JAMA Neurol. 2019;76:701-709.
Wong BL, Rybalsky I, Shellenbarger KC, et al. Long-term outcome of interdisciplinary management of patients with Duchenne muscular dystrophy receiving daily glucocorticoid treatment. J Pediatr. 2017;182:296-303. e.1.
Ma J, McMillan HJ, Karaguzel G, et al. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int. 2017;28:597-608. https://doi.org/10.1007/s00198-016-3774-5
Allen CS, Yeung JH, Vandermeer B, Homik J, Cochrane Musculoskeletal Group. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10:CD001347.
Tian C, Wong BL, Hornung L, et al. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. Neuromuscul Disord. 2020;30:599-610.
Srinivasan R, Rawlings D, Wood CL, et al. Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy. Muscle Nerve. 2016;54:79-85.
Palomo Atance E, Herrera MJB, de La Plata MAM, et al. Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy. An Pediatr (Barc). 2011;74:122-125.
Houston C, Mathews K, Shibli-Rahhal A. Bone density and alendronate effects in Duchenne muscular dystrophy patients. Muscle Nerve. 2014;49:506-511.
Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, Biggar WD. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil. 2005;86:284-288.
Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
Weber DR, Boyce A, Gordon C, et al. The utility of DXA assessment at the forearm, proximal femur, and lateral distal femur, and vertebral fracture assessment in the pediatric population: 2019 ISCD official position. J Clin Densitom. 2019;22:567-589.
Ward LM, Hadjiyannakis S, McMillan HJ, Noritz G, Weber DR. Bone health and osteoporosis management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142:S34-S42.
Lentle B, Koromani F, Brown JP, et al. The radiology of osteoporotic vertebral fractures revisited. J Bone Miner Res. 2019;34:409-418.
Ward LM, Ma J, Lang B, et al. Bone morbidity and recovery in children with acute lymphoblastic leukemia: results of a six-year prospective cohort study. J Bone Miner Res. 2018;33:1435-1443.
Ma J, Siminoski K, Alos N, et al. The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures. J Clin Endocrinol Metab. 2015;100:1018-1027.
Che H, Breuil V, Cortet B, et al. Vertebral fractures cascade: potential causes and risk factors. Osteoporos Int. 2019;30:555-563.
Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord. 2011;21:298-303.
Nasomyont N, Keefe C, Tian C, et al. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Osteoporos Int. 2020;31:2449-2459.
Sbrocchi AM, Rauch F, Jacob P, et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int. 2012;23:2703-2711.
Allington N, Vivegnis D, Gerard P. Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthop Belg. 2005;71:91-97.
Ronsley R, Islam N, Kang M, et al. Effects of bisphosphonate therapy on bone mineral density in boys with Duchenne muscular dystrophy. Clin Med Insights Endocrinol Diabetes. 2020;13:179551420972400.
Nasomyont N, Hornung LN, Gordon CM, Wasserman H. Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review. Bone. 2019;121:60-67.
Ivanyuk A, Garcia Segarra N, Buclin T, et al. Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution. Neuromuscul Disord. 2018;28:865-867.
Lemon J, Turner L, Dharmaraj P, Spinty S. Rhabdomyolysis and myoglobinuria following bisphosphonate infusion in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2019;29:567-568.
Wu M, Flanagan J, Loechner K. Impact of the COVID-19 pandemic on patients with osteogenesis imperfecta. JBMR Plus. 2021;5:e10458.